Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-β by Sternberg, Zohara et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Journal of Neuroinflammation
Open Access Research
Immunomodulatory responses of peripheral blood mononuclear 
cells from multiple sclerosis patients upon in vitro incubation with 
the flavonoid luteolin: additive effects of IFN-β
Zohara Sternberg*1, Kailash Chadha2, Alicia Lieberman2, Allison Drake1, 
David Hojnacki1, Bianca Weinstock-Guttman1 and Frederick Munschauer1
Address: 1Department of Neurology, Baird MS Center, Jacobs Neurological Institute, Buffalo, NY, USA and 2Department of Molecular & Cellular 
Biology, Roswell Park Cancer Institute, Buffalo, NY, USA
Email: Zohara Sternberg* - zs2@buffalo.edu; Kailash Chadha - kailash.chadha@roswellpark.org; 
Alicia Lieberman - alicialieberman@gmail.com; Allison Drake - adrake@thejni.org; David Hojnacki - hojnacki@buffalo.edu; Bianca Weinstock-
Guttman - bguttman@thejni.org; Frederick Munschauer - fmunschauer@thejni.org
* Corresponding author    
Abstract
The study is aimed to determine the role of luteolin (3',4',5,7-tetrahydroxyflavone), alone and in
combination with human interferon-beta (IFN-β), in modulating the immune response(s) of
peripheral blood mononuclear cells (PBMCs) isolated from multiple sclerosis (MS) patients. PBMC
proliferation in the presence or absence of these drugs was determined and the production of pro-
inflammatory cytokines (IL-1β, TNF-α), and the ratio of cell migration mediator MMP-9, and its
inhibitor, TIMP-1 was assessed in the culture supernatants. Luteolin reduced, in a dose-dependent
manner, the proliferation of PBMCs, and modulated the levels of IL-1β and TNF-α released by
PBMCs in the culture supernatants. Luteolin reduced the MMP-9/TIMP-1 ratio via lowering MMP-
9 production. In the majority of cases, luteolin, when combined with IFN-β, had additive effects in
modulating cell proliferation, IL-1β, TNF-α, MMP-9 and TIMP-1.
Background
Flavonoids, are group of polyphenolic compounds,
known to have significant anti-tumor, antioxidant and
anti-inflammatory activities [1]. Epidemiological studies
have shown that high intake of fruit and vegetables, rich
in flavonoids, is protective against various forms of cancer
[2], cardiovascular diseases [3] and neurodegenerative
diseases [4]. Luteolin, 3',4',5,7-tetrahydroxyflavone, an
important member of the flavonoid family has shown to
exert immunomodulatory effects that may be beneficial in
the treatment of neurodegenerative diseases such as mul-
tiple sclerosis (MS), which has an underlying T-cell medi-
ated autoimmune pathology [5].
In vitro studies show that luteolin inhibits T cell activation
[6] and reduces the proliferation of autoreactive T-cells
induced by both alpha B-crystallin and the murine
encephalitogen proteolipid protein peptide (PLP), candi-
date autoantigens in MS and experimental autoimmune
encephalomyelitis (EAE) respectively [7]. In addition,
luteolin blocks myelin basic protein-induced mast cells'
stimulation which are capable of activating T-cells [8,9].
Furthermore, luteolin has been shown to reduce induc-
tion of proinflammatory cytokine from LPS-stimulated
human peripheral blood mononuclear cells (PBMC) [10],
LPS-stimulated dendritic cells [11] and IL-1β-activated
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astrocytes in culture [12]. A recent study shows that inter-
peritoneal administration (50 mg/kg) or oral treatment
(100 mg/kg) of luteolin suppresses clinical symptoms of
EAE and prevents relapse when administered either before
or after EAE disease onset [13]. The EAE suppression by
luteolin is related in part to its ability to inhibit mast cell
activation [8]. The activation of brain mast cells, which are
located perivascularly, results in an increase in blood
brain barrier permeability [14] and the release of
cytokines and chemokines necessary for the migration of
activated T-cells into the CNS, thereby facilitating T-cell-
mediated inflammatory processes [15].
Luteolin and its glucoside metabolite, luteolin 7-O-gluco-
side, are potent inhibitor of MMP-9 activity [16], suggest-
ing that luteolin may interfere with the migration of
activated immune cells into the CNS via modulation of
proteins crucial for this migration [17]. This notion is sup-
ported by an in vivo study showing that luteolin treatment
prevents monocyte migration across the brain endothe-
lium, resulting in reduction of inflammation and axonal
damage in the CNS of the EAE mice [13].
The immunomodulatory effects of luteolin are similar to
those of its close relative quercetin (3,3',4',5,7-pentahy-
droxyflavone). However, in vitro and in vivo studies show
that luteolin has enhanced immunomodulatory activities
compared to quercetin [10,13,18-20]. Studies of human
PBMC treated with 5 μM flavonoids show that this con-
centration of quercetin is less effective in reducing TNF-α
production, than is a similar concentration of luteolin
which reduces TNF-α production by more than 50% [10].
Similar results were shown in studies using murine mac-
rophages [18,19]. In addition, luteolin has been shown to
reduce MMP-9 activity in A431 tumor cells more effec-
tively than quercetin [20]. These in vitro results are further
supported by the in vivo study showing that IP administra-
tion of 50 mg/kg luteolin from day six after disease induc-
tion reduces the mean clinical scores of EAE by
approximately 25% while IP administration of luteolin is
effective by more than 80% [13].
In a recent study [21], we examined immunomodulatory
effects of quercetin in PBMCs derived from MS patients.
We observed a significant effect of quercetin at concentra-
tions of >5 μM. However, this concentration is above the
0.1  μM fasting plasma concentration of quercetin
achieved by a normal daily diet containing 23-34 mg of
flavonoids [22]. Therefore, this study investigated
whether luteolin could exert immunomodulatory effects,
at near physiological concentrations when used alone or
in combination with interferon beta (IFN-β) upon iso-
lated PBMCs from MS patients.
Material and methods
Population
14 relapsing remitting (RR) MS patients (8 females and 6
males) were recruited into the study. Patients were clini-
cally stable with an age ranging between 31-57 yrs (mean
44.9 ± 8.0) diagnosed with MS according to the McDon-
ald criteria [23] and EDSS range between 0-8.0 (mean of
3.6 ± 2.5). Patients were newly diagnosed or were naïve to
all disease modifying therapies including IFN-β, glati-
ramer acetate and natalizumab for the last 6 months, and
were not taking glucocorticoids during the last 30 days.
Pregnant patients and patients with other inflammatory
diseases were excluded from the study. Informed consent,
based upon IRB approval protocol was obtained from all
subjects.
Reagents
Luteolin (3',4',5,7-tetrahydroxyflavone), phytohemagglu-
tinin (PHA) and Ficoll-Hypaque were purchased from
Sigma Aldrich (St Louis, MO, USA). Luteolin was dis-
solved in DMSO and added in concentrations that did not
exceed 0.05% of the total volume in any of the experi-
ments. IFN-β was obtained from Biogen Idec Inc (Cam-
bridge, MA). RPMI 1640 medium, fetal bovine serum
(FBS) and antibiotics were purchased from InVitrogen
(Grand Island, NY). Quick Cell Proliferation Assay Kit was
purchased from BioVision Inc. (Mountain View, CA).
ELISA kits for total MMP-9, and TIMP-1 were purchased
from Amersham Biosciences (Piscataway, NJ). ELISA kits
for TNF-α and IL-1β were purchased from R&D systems
(Minneapolis, MN). Unless otherwise specified all other
reagents were of analytical grade.
Isolation of peripheral blood mononuclear cells
Twenty milliliters of venous blood was obtained from
each subject. Peripheral blood mononuclear cells
(PBMCs) were isolated using Ficoll-Hypaque isolation
technique and cells were washed three times with PBS and
counted prior to their use in any experiment. Cell viability
was determined by trypan blue dye.
Proliferation assay
For cell proliferation assays, PBMCs were plated in 96 well
tissue culture plates at a density of 5 × 104 cells/ml, 200 μl/
well in complete RPMI 1640 medium. Cells were stimu-
lated with 2 μg/ml of PHA for 48 hrs in the presence of
either 0, 0.2, 1, 5,10, 25, 50 μM of luteolin, 2 IU of IFN-β,
or a combination of 0. 0.2, 1, 5, 10 μM of luteolin, and 2
IU of IFN-β. PBMCs proliferation was measured by Quick
Cell Proliferation Assay Kit.http://www.biovision.com/
products/k301.html.
Cytokines and chemokines measurements
For measurement of proinflammatory cytokines, MMP-9
and TIMP-1, PBMCs were plated at the density of 1 × 106Journal of Neuroinflammation 2009, 6:28 http://www.jneuroinflammation.com/content/6/1/28
Page 3 of 8
(page number not for citation purposes)
cells/ml in 24-well tissue culture plates in the same culture
medium as for cell proliferation assay. Cells were stimu-
lated for 48 h with 2 μg/ml of PHA in the absence or pres-
ence of either luteolin and IFN-β, or a combination of
luteolin and IFN-β. The concentrations of luteolin and
IFN-β were similar to those used for cell proliferation
assay. The choice of 2 IU IFN-β is based upon two obser-
vations. First, this interferon level is within the steady state
concentration of 2-10 IU/ml achieved in patients receiv-
ing 6 × 106 IU of IFN-β (Avonex) given intramuscularly
once a week. Second, our own preliminary in vitro experi-
ments have shown that 2 IU of IFN-β reduces MMP-9 pro-
duction by approximately 10-15%. This low percent
inhibition was chosen to see possible synergistic effects of
IFN-β when combined with various concentrations of
luteolin.
Culture supernatants were collected after 48 hours of
treatment, spun for 10 min at 2,000 rpm, and stored at -
80°C. The proinflammatory cytokines, total MMP-9 and
TIMP-1 were all measured by sandwich ELISA as per
instructions provided by the manufacturers. The detection
limits were 1.9 pg/ml for IL-1β, 15.6 pg/ml for TNF-α and
31.25 pg/ml for both MMP-9 and TIMP-1. All measure-
ments were performed in duplicate, and mean values of
the two measurements were used for statistical analysis.
Absorbance was measured at 450 nm in a μ Quant Micro-
plate reader system (BioTek Instruments, Inc).
Statistical analysis
Dose responses of luteolin, for each dependant measure
of inflammation (cell proliferation, IL-1β, TNF-α, MMP-9
and TIMP-1) were assessed using analysis of variance with
luteolin concentration (0-50 μM) and type of treatment
(luteolin single and or combined with 2IU IFN-β). The
differences between means were performed using post hoc
contrasts. Additionally, cell proliferation was included as
a covariate in order to control for its effect in models
examining luteolin effect on IL-1β, TNF-α, MMP-9 and
TIMP-1.
Results
Proliferative responses of PBMC's to luteolin
Luteolin inhibited PBMCs proliferation in a dose-depend-
ent manner (Figure 1). Luteolin's effect on cell prolifera-
tion was significant at concentrations of ≥0.2  μM
(reduction of 5.9 ± 1.2% (0.154 ± 0.02 OD vs. 0.145 ±
0.01 OD, p = 0.01). At 50 μM luteolin, PBMC prolifera-
tion was reduced by 38% with no cytoxicity as indicated
by trypan blue dye exclusion test. Similarly, 2IU of IFN-β
(Figure 1, luteolin 0 μM) reduced cell proliferation by
approximately 8.5 ± 2.1% (p < 0.001). IFN-β combined
with luteolin reduced cell proliferation by an additional
4.9 ± 2.2% across all luteolin's concentrations, but this
additive effect was not statistically significant (p values >
0.05).
Effect of luteolin upon production of pro-inflammatory 
cytokines by PBMC
Figure 2A and 2B represent the production of IL-1β and
TNF-α respectively, in response to luteolin alone and in
combination with IFN-β by PBMCs of MS patients. Luteo-
lin reduced the production of IL-1β and TNF-α in a dose-
dependent manner. The effect of luteolin was significant
at concentrations of ≥0.2 μM with a reduction of 10.7 ±
1.8% (from 882.4 ± 110 pg/ml to 786.5 ± 99 pg/ml, p <
0.001) and 12.3 ± 2.2% (from 1988.1 ± 258.3 pg/ml to
1749.8 ± 228.7 pg/ml, p < 0.001) in IL-1β and TNF-α
respectively. At a concentration of 50 μM, luteolin
reduced IL-1β and TNF-α production by 88% and 94%
respectively. The effects of luteolin on the production of
IL-1β and TNF-α remained significant after correcting for
the possible effects of luteolin on cell proliferation (p <
0.001).
IFN-β at 2 IU (Figures 2A and 2B, luteolin 0 μM) reduced
IL-1β and TNF-α production by approximately 9.0 ± 4.1%
(p = 0.03) and 12.0 ± 3.0% (p < 0.001), respectively. IFN-
β combined with luteolin tended to reduce IL-1β and
TNF-α production by a respective average of 12.70 ± 2.8%
(p values between 0.1-0.03) and 15.4 ± 1.5% (p values
between 0.1-0.02) across all luteolin concentrations.
Effect of luteolin upon MMP-9 production by PBMC
Luteolin reduced the production of total MMP-9 released
by PBMC's from MS patients in the culture supernatant in
a dose-dependent manner (Figure 3A). The effects of lute-
olin on MMP-9 production was significant at concentra-
tions of ≥0.2 μM (reduction of 9.0 ± 1.8%, from 7233.1 ±
1171pg/ml to 6593.8 ± 1095 pg/ml, p < 0.001). Luteolin
at a concentration of 50 μM reduced MMP-9 production
by a maximal of 98%. The effect of luteolin on the reduc-
Dose-dependent effects of luteolin in combination with 2 IU  of IFN-β upon PHA-dependent proliferative responses Figure 1
Dose-dependent effects of luteolin in combination 
with 2 IU of IFN-β upon PHA-dependent proliferative 
responses. PBMCs derived from MS patients were incu-
bated in the presence of 0.2-50 μM luteolin and 0.2-10 μM 
luteolin in combination with 2IU IFN-β. Values expressed are 
a percentage of maximum response (% of control). Data is 
average mean ± SE of 14 MS patients. Abbrev: Lu = luteolin.
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tion of MMP-9 remained significant after correcting for
the effect of luteolin on cell proliferation (p < 0.001). IFN-
β (2 IU) reduced MMP-9 production by 13.2 ± 0.2% (p <
0.001). 2 IU IFN-β (Figure 3A, luteolin 0 μM) tended to
reduce MMP-9 production by an average of 7.3 ± 0.5% (p
values between 0.02-0.007) across all luteolin concentra-
tions used.
Effect of luteolin upon TIMP-1 production by PBMC's
Luteolin reduced TIMP-1 production dose-dependently,
and this reduction was statistically significance at concen-
trations of luteolin ≥ 0.2 μM where it reduced TIMP-1 by
an average of 8.5 ± 5.9% (from 20748 ± 2515 pg/ml to
19193 ± 2499 pg/ml, p = 0.05). Luteolin at a concentra-
tion of 50 μM reduced TIMP-1 by an average of 64%.
However, the effect of luteolin on TIMP-1 was not signifi-
cant after correcting for the possible effects of luteolin on
cell proliferation (p = 0.07). IFN-β (2 IU) reduced TIMP-1
production by 13.8 ± 4.2% (p = 0.009) (Figure 3B). The
combination of luteolin and IFN-β (Figure 3B, luteolin 0
μM) tended to reduce TIMP-1 by 20.7 ± 5.2% (p values
between 0.2-0.01) across all luteolin concentrations used.
MMP-9/TIMP-1 ratio in response to luteolin
Luteolin reduced the ratios of MMP-9 to TIMP-1 released
in the culture supernatants. The reduction in MMP-9/
TIMP-1 ratio was statistically significant at concentrations
of luteolin ≥ 10 μM (from 0.229 ± 0.03 to 0.139 ± 0.02, p
= 0.04). IFN-β alone had no effect on this ratio (p = 0.9).
MMP-9/TIMP ratio was not different with luteolin com-
pared to luteolin+IFN-β (p values between 0.2-0.9) (Fig-
ure 3C).
Discussion
This study provides evidence that luteolin exerts beneficial
immunomodulatory effect(s) on PBMCs derived from MS
patients. Luteolin, in a dose-dependent manner, reduced
PBMC proliferation and production of several pro-inflam-
matory mediators (IL-1β, TNF-α, and MMP-9) that are
crucial in MS pathological processes. The results observed
with luteolin are similar to those reported earlier for quer-
cetin [21]. The reduction in production of pro-inflamma-
tory cytokines is independent of the effects of luteolin on
cell proliferation. The importance of immune mecha-
nisms in the pathogenesis of MS is well established, since
proliferation of myelin-activated cells and the subsequent
production of proinflammatory mediators facilitate their
migration into the CNS [24], promoting neuronal cell
injury.
The effects of luteolin on the degrees of inhibition of IL-
1β, TNF-α and MMP-9 were significant at concentrations
of 0.2 μM. These inhibitory values are significantly lower
than the respective values observed with quercetin in our
previous study [21]. The immunomodulatory effects of
luteolin at these low concentrations are especially encour-
aging since these fall in the realm of plasma concentra-
tions of approximately 1.5 μM observed with
supplementation of 1 g/day flavonoids [25].
The pharmacological actions of luteolin, combined with
its enhanced potency, may be especially attractive in the
treatment of MS since, beyond the modulation of periph-
eral immune cells, luteolin has also been shown to exert
immunomodulatory effects inhibiting LPS-induced
microglial activation both in vitro and in vivo [26]. The
immunomodulatory effects of luteolin on CNS-resident
cells are likely to result in neuroprotection, since there is a
linear relationship between extent of microglial activa-
tion, demyelination and axonal injury [27]. Similar neu-
roprotective effects of luteolin have also been observed in
rat neural PC12 and glial C6 cells in culture [28,29], and
in an in vivo model of permanent middle cerebral artery
occlusion [29].
Dose-dependent effects of luteolin in combination with 2 IU  of IFN-β upon PHA-dependent production of IL-1β (2A) and  TNF-β (2B) in cell culture supernatant Figure 2
Dose-dependent effects of luteolin in combination 
with 2 IU of IFN-β upon PHA-dependent production 
of IL-1β (2A) and TNF-β (2B) in cell culture superna-
tant. PBMCs derived from MS patients were incubated in 
the presence of 0.2-50 μM luteolin and 0.2-10 μM luteolin in 
combination with 2IU IFN-β. Values expressed are a percent-
age of maximum response (% of control). Data is average 
mean ± SE of 14 MS patients. Asterisks indicate significant dif-
ferences between luteolin and luteolin in combination with 
2IU of IFN-β, P ≤ 0.05 is significant. Abbrev: Lu = luteolin.
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Luteolin reduced MMP9/TIMP-1 ratios via a steeper
reduction in MMP-9 relative to TIMP-1. This reduction in
MMP-9/TIMP-1 ratio further supports a neuroprotective
effect for luteolin, since a higher ratio has been shown to
be positively associated with disease activity assessed by
both the clinical as well as MRI data [30,31]. MMP-9/
TIMP-1 ratios are significantly altered in MS lesions [32]
and changes in MMP-9 levels are known to contribute to
the disruption of the blood-brain barrier and degradation
of extra-cellular matrix [33], activities which are regulated
by its endogenous inhibitor TIMP-1. Furthermore, MMP-
9 can directly cause axonal injury, independent of its effect
on blood-brain barrier integrity [34].
Pharmacological effects of flavonoids seem to be depend-
ent on specific structural features of individual flavonoids.
Analysis of structure-activity relationships indicate that
the immunomodulatory effects of flavonoids depend on
the position, number and substitution of the hydroxyl
group of the B ring, and on saturation of the C2-C3 bond
[18,35]. Although quercetin and luteolin have similar
structures (Figure 4), the lack of the hydroxyl group at the
C-3 position of luteolin may account for the enhanced
immunomodulatory effects observed in this study, as well
as luteolin's superior ability to inhibit myelin phagocyto-
sis by macrophages, when compared to quercetin [36].
The immunomodulatory effects of luteolin and related
flavonoids has been attributed mainly to the regulation of
signaling pathways involving nuclear factor kappaB (NF-
kappaB) activation and mitogen-activated protein (MAP)
kinase family phosphorylation [10,37]. However,
mitogen-induction of NF-kappaB involves many steps
including mitogen-induced IkappaB kinase (IKK) activa-
tion, IkappaB degradation, DNA binding activity of NF-
kappaB complex and its nuclear translocation.
Luteolin has been shown to affect both the upstream (IKK
activation (IkappaB degradation) and the downstream
(DNA binding activity and nuclear translocation) signal-
ing pathways of LPS-induced NF-kappaB activation in
murine macrophages [19,38]. Quercetin, on the other
hand, inhibits LPS-induced NF-kappaB activation via
inhibiting IKK activation and IkappaB degradation, with-
out affecting DNA binding activity and nuclear transloca-
tion of NF-kappaB complex [39,40].
In addition, the treatment of LPS- stimulated RAW 264.7
macrophages with quercetin has been shown to inhibit
the activation of phosphorylated ERK MAP kinase and
p38 MAP kinase but not JNK MAP kinase [41]. However,
luteolin has been shown to inhibit the three MAP kinases
in LPS-stimulated macrophages and microglia [42,43].
The differences in the regulation of signaling pathways
involved in LPS-induced activation of NF-kappaB and
MAP kinases may be related to the structural differences
between the two compounds resulting in enhanced
immunomodulatory potency of luteolin compared to
quercetin.
Nevertheless, this enhanced immunomodulatory effect of
luteolin may depend not on the parent compounds, but
Dose-dependent effects of luteolin in combination with 2 IU  of IFN-β upon PHA-dependent production of MMP-9 (3A)  and TIMP-1 (3B) and MMP-9/TIMP-1 ratio (3C) in cell culture  supernatant Figure 3
Dose-dependent effects of luteolin in combination 
with 2 IU of IFN-β upon PHA-dependent production 
of MMP-9 (3A) and TIMP-1 (3B) and MMP-9/TIMP-1 
ratio (3C) in cell culture supernatant. PBMCs derived 
from MS patients were incubated in the presence of 0.2-50 
μM luteolin and 0.2-10 μM luteolin in combination with 2IU 
IFN-β. Values of 3A and 3B expressed are a percentage of 
maximum response (% of control). Data is average mean ± 
SE of 14 MS patients. Values of MMP-9/TIMP-1 ratio were 
obtained by dividing each indicated concentration of MMP-9 
with corresponding concentration of TIMP-1. Asterisks indi-
cate significant differences between luteolin and luteolin in 
combination with 2IU of IFN-β, P < 0.05 is significant. 
Abbrev: Lu = luteolin.
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on their biotransformation to their respective cellular
metabolites [44]. The free C-3 hydroxyl group plays an
important role in quercetin's immunomodulatory effects
[45]. However, depending on the cellular enzymatic pat-
tern, this hydroxyl group is often subject to glucuronida-
tion, glycosylation, methylation or acetylation [46]. The
glycosylation or methylation of the hydroxyl group at the
C-3 position has been shown to result in the loss of the
antiviral activity of quercetin [47]. Similarly, glycolysation
at the c-3 position causes loss of quercetin's antiplatelet
activity [48], supporting the notion that quercetin metab-
olites often have reduced immunomodulatory effects
compared to the parent compound [49].
The enhanced immunomodulatory effects of luteolin in
PBMCs compared to quercetin is consistent with the
reported results in the EAE model where luteolin sup-
pressed EAE clinical symptoms more effectively than
quercetin [13]. In this latter study, the immunomodula-
tory effects of luteolin were attributed to the modulation
of cytoskeletal regulatory components such as the family
of the Rho GTPases. Rho GTPases are known to inhibit
NF-kappaB [50]. The inhibition of NF-kappaB could lead
to the reduction of MMP-9 [51] observed in our study. It
is noteworthy that the efficacy of luteolin in the EAE
model is dependent in part on the nature of the antigenic
peptide employed, as it has shown to reduce EAE mean
clinical scores more effectively in myelin basic protein-
induced EAE vs. proteolipid protein-induced EAE [52].
The importance of new compound(s) in the treatment of
MS is emphasized by the sub-optimal efficacy of current
drugs used in the treatment of MS, including IFN-β, which
is the most commonly prescribed disease modifying treat-
ment for relapsing MS. The combination of luteolin and
IFN-β enhances the immunomodulatory effects of the lat-
ter on most measured variables. Therefore, this combina-
tion therapy (luteolin+IFN-β) may improve the clinical
efficacy of IFN-β by reducing the level needed for optimal
therapeutic effects, hence reducing the likelihood for
development of circulating neutralizing antibodies that
are known to reduce the efficacy of IFN-β therapy [53].
A review of the data related to the safety of flavonoids sup-
port their use as a dietary supplement and as food enrich-
ment [54]. Although, there are no peer reviewed studies
on luteolin, the safety of dietary supplementation of 1 g/
day of its close relative, quercetin, in humans, has been
documented [55]. Moreover, a study in rodents showed
no toxicity of luteolin (up to10 mg/kg given IP) adminis-
tered daily for 18 days, as evidenced by normal food
intake and body weight [56].
Nevertheless, low intestinal absorption of flavonoids in
general [57] limits their expected beneficial effects in
humans. Similar to quercetin, luteolin is found in nature
in the form of glycosides [58]. Upon ingestion, luteolin
glycosides are cleaved to their biologically active free form
(aglycone) in the intestinal mucosa [58]. Luteolin agly-
cone is subsequently absorbed, and mostly glucuroni-
dated soon after [58]. However, flavonoids' metabolites
have reduced biological activities when compared to the
parent compound [59].
Human ingestion of bolus dose of 50 mg luteolin has
been shown to lead to a peak plasma concentration of
0.05 μmol (total luteolin and its metabolites) after 2 h
[60]. This plasma level is similar to the concentration of
luteolin aglycone which showed biological activities in
our in vitro study. Assuming that a percentage of ingested
luteolin could be found in the plasma in the form of agly-
cone [61], combined with the likelihood of luteolin
deglucuronidation during inflammatory processes [62],
suggest that luteolin supplementation may lead to its
accumulation in tissues [63] such as blood, raising its con-
centrations to the realm of plasma levels with therapeutic
implication in patients with chronic inflammatory and
neurodegenerative diseases such as MS.
We have shown that flavonoids luteolin and quercetin are
potent in vitro inhibitors of proinflammatory markers and
could beneficially modulate markers of neuroprotection/
The structures of quercetin and luteolin Figure 4
The structures of quercetin and luteolin.
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neurodegeneration such as the MMP-9/TIMP- ratio. Our
in vitro observations are consistent with the reported ben-
eficial effects of luteolin when used by MS patients as
adjunctive therapy [64], further reiterating the need for
ccontrolled, evidence-based clinical trials with flavonoids
in general and with luteolin in particular.
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